Acalabrutinib Intermediate Crystallization for Filterable High Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic methods for acalabrutinib are not suitable for large-scale manufacturing, lacking in purity, yield, and process control, and are environmentally unfriendly.
Innovation Solution
Improved processes involving controlled reaction conditions, such as temperature and catalyst use, to maintain chiral purity and reduce impurities, along with solvent optimization and in situ bromination, enable high-yield production of acalabrutinib intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If previously reported synthetic methods are used, then the synthesis can be performed, but the compound purity is insufficient and the process is not suitable for large-scale manufacture
Solution Approach 1:
The patent modifies reaction parameters including temperature control, solvent selection, and reagent ratios to achieve both high purity and scalability. Specifically, the process uses controlled temperature ranges and optimized solvent systems to maintain product quality while enabling large-scale production
Solution Approach 2:
The patent employs selective isolation techniques to remove impurities from the reaction mixture, achieving high compound purity. The process separates the desired product from reaction by-products through controlled crystallization and filtration steps
2Ease of manufacture
If previously reported synthetic methods are used, then the synthesis can be performed, but the compound isolation and filterability are poor
Solution Approach 1:
The patent utilizes controlled phase transitions, specifically crystallization from solution, to achieve both easy isolation and high purity. The process controls solvent evaporation and cooling rates to produce filterable crystalline material with high purity
Solution Approach 2:
The patent performs preliminary optimization of crystallization conditions before scale-up, ensuring that the isolation process yields both high purity and good filterability. This includes pre-determination of optimal solvent ratios and cooling profiles
3Productivity
If previously reported synthetic methods are used, then the synthesis can be performed, but the cycle time is excessive
Solution Approach 1:
The patent divides the synthesis into discrete, optimized reaction steps with clear work-up and isolation procedures. This segmentation allows for efficient scale-up and reduces overall cycle time while maintaining reliable process control at each stage
Solution Approach 2:
The patent implements continuous processing where possible, such as direct transfer of reaction mixtures between steps without intermediate isolation, reducing cycle time while maintaining product quality through controlled continuous processing
4Ease of manufacture
If previously reported synthetic methods are used, then the synthesis can be performed, but the cost is high and regulatory compliance is difficult
Solution Approach 1:
The patent employs cost-effective, readily available reagents and solvents that simplify regulatory compliance. The process uses common pharmaceutical-grade materials that reduce both cost and regulatory burden while maintaining high product purity through optimized reaction conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved processes achieve high chiral purity and yield, reduce environmental impact, and enhance process robustness for large-scale manufacturing of acalabrutinib.
Implementation Method 1
contacting a compound having the structure of Formula (VII) with 2-butynoic acid, or a salt thereof, in the presence of 1-propylphosphonic anhydride and a base in a reaction medium to form a reaction mixture comprising the compound of Formula (VIII)
Implementation Method 2
contacting a compound having the structure of Formula (VII) with 2-butynoic acid, or a salt thereof, in the presence of 1-propylphosphonic anhydride and a base
Implementation Method 3
contacting a compound having the structure of Formula (V) with a compound having the structure of Formula (VI) in the presence of a base and a palladium catalyst in an aqueous reaction medium
Implementation Method 4
controlled reaction conditions, such as temperature and catalyst use, to maintain chiral purity and reduce impurities
Data Source
AI summary
The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.